Endeavor BioMedicines’ Post

Vicore Pharma AB is pleased to announce positive final results from the Phase 2a AIR trial demonstrating that buloxibutid improves lung function over 36 weeks in patients with idiopathic pulmonary fibrosis (#IPF). These encouraging results were presented yesterday by Toby Maher, Keck School of Medicine of USC, as a late-breaking oral session at the American Thoracic Society International Congress (#ATS2024). Vicore will be discussing the results in more detail during a webinar on Wednesday 5/22 at 10:00 ET/16:00 CET. You can register for the webinar here: https://lnkd.in/eKp8xYGj #pulmonaryfibrosis #biotechnews #respiratory #clinicaldata

We're so pleased to report positive final results for Vicore Pharma AB's AT2 receptor agonist, buloxibutid, in the Phase 2a AIR study in IPF, reflecting disease-modifying potential. We believe that agonizing an upstream pathway impacting precursor alveolar epithelial type II cells is a excellent approach to this tough disease and are looking forward to initiating the Phase 2b ASPIRE study to advance this exciting molecule! #ATS2024 #IPF #PulmonaryFibrosis

Not long to go until the PROMs Research Conference! Get in touch at https://bit.ly/4aPkmTV to arrange a chat with our team. We will be presenting the following posters at the event: Poster 1: Patient-reported outcome measures used in interventional studies of irritable bowel syndrome: a targeted review Poster 2: Outcomes and interventions in clinical studies investigating pharmacological therapies for the treatment of transthyretin amyloidosis: a targeted review https://bit.ly/4cb2sML

👨🏻⚕️ Healthcare Professionals, New clinical case by Curium Pharma 👉 Role of myocardial perfusion imaging with SPECT in coronary artery disease ✅ Free Registration 🕐 20 minutes 👨🏻⚕️ Hosted by Fabien Hyafil 💻 The presentation will begin with theoretical reminders before exposing an interactive clinical case. It will finish with a summary. Benefit from the expertise of a specialist to:  ✔️ Discuss the value of stress myocardial perfusion imaging with SPECT ✔️ Evaluate patients with stable coronary artery disease Free registration on Invivox via the following link : go2.invivox.com/44fT1bR Curium Pharma

Click here for the full content: https://bit.ly/CT-807475 On Tuesday, October 31, #Adaptimmune updated its corporate deck and published 2 press releases announcing clinical updates from lete-cel (NY-ESO1 TCR-T) and afami-cel (MAGE-A4 SPEAR-T) to be presented at #CTOS2023 (November 1-4): • An interim analysis of the pivotal Ph2 IGNYTE-ESO (https://bit.ly/40pBU5r) trial evaluating lete-cel in r/r #synovialsarcoma (#SS) or myxoid/round cell liposarcoma (#MRCLS) (press release: https://bit.ly/3MqJRl6) • Interim results of Ph2 IGNYTE-ESO (https://bit.ly/40pBU5r) trial’s Substudy 1 (https://bit.ly/47jPl9E) evaluating lete-cel in treatment-naïve metastatic or unresectable SS or MRCLS patients • Data from Cohort 1 of afami-cel’s pivotal Ph2 SPEARHEAD-1 (https://bit.ly/3sswEl3) study in advanced SS (press release: https://bit.ly/3QnkSk2)

In December 2023, the FDA approved a groundbreaking gene-editing treatment for sickle cell disease. Now, the final results from the pivotal clinical trial are published in the New England Journal of Medicine. This study, coauthored by UIC’s Dr. Damiano Rondelli, reveals that the therapy significantly reduces painful symptoms. We're proud of Dr. Rondelli's contributions to this major medical milestone! Read the full story: https://loom.ly/l8F4_cM #UICAlumni #MedicalBreakthrough #UIC #UICProud #SickleCellDisease #UICHealth #UICResearch

💡“𝗙𝗿𝗼𝗺 𝗘𝘀𝗰𝗮𝗹𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗪𝗲𝗮𝗻𝗶𝗻𝗴 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀—𝗛𝗼𝘄 𝘁𝗼 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲 𝘁𝗵𝗲 𝗘𝗖𝗠𝗘𝗟𝗟𝗔 𝗖𝗼𝗻𝗰𝗲𝗽𝘁.” Benedikt Schrage, MD, discusses his paper, “From Escalation to Weaning Strategies—How to Integrate the ECMELLA Concept.” He explains the rationale behind the ECMELLA approach, which combines mechanical circulatory support (MCS) with an Impella® device with veno-arterial extracorporeal membrane oxygenation (VA ECMO); he describes why it is relevant in the treatment of patients with cardiogenic shock. 𝗧𝘄𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝗰𝗲𝗻𝗮𝗿𝗶𝗼𝘀 𝗶𝗻 𝘄𝗵𝗶𝗰𝗵 𝗲𝘀𝗰𝗮𝗹𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗘𝗖𝗠𝗘𝗟𝗟𝗔 𝘀𝗵𝗼𝘂𝗹𝗱 𝗯𝗲 𝗰𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗲𝗱, 𝗮𝗰𝗰𝗼𝗿𝗱𝗶𝗻𝗴 𝘁𝗼 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻, 𝗮𝗿𝗲: 1️⃣ Patient has deteriorating cardiogenic shock (SCAI stage D or E) despite treatment with a mAFP and VA ECMO is added to augment cardiac output and increase tissue perfusion and oxygenation 2️⃣ Patient in severe cardiogenic shock (SCAI stage D or E) requires immediate VA ECMO for tissue perfusion/oxygenation and mAFP to unload the LV and facilitate myocardial recovery

📅 Save the Date: Join LifeSci Events and Disc Medicine for a virtual "Lunch with LifeSci" event on September 14th at 1:00 PM EDT! Disc Medicine is a clinical-stage #biotech company pioneering groundbreaking treatments for rare #BloodDiseases, erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), affecting 8,000 people in the US and Europe. 💡 What to Expect: 👉 Gain insights into Disc Medicine's transformative drug, Bitopertin, designed to alleviate extreme pain and skin damage triggered by sunlight exposure in EPP and XLP patients. 👉 Learn about Bitopertin's impressive 40% reduction in toxic byproduct PPIX, leading to enhanced quality of life and a 96% decrease in phototoxic reactions. 👉 Get a sneak peek into Disc Medicine's upcoming Phase 2 trial results for AURORA, promising even more progress. 👉 Explore Disc's second asset, DISC-0974, with potential applications in anemias associated with inflammatory diseases. 👉 Hear from John Quisel about the company's future and its exciting potential in the world of blood diseases. Reserve your seat: https://lnkd.in/e8vVmhB3 #LifeSciEvent #LifeSciences

We're still reflecting on the incredible scientific advancements shared in 2023. Dr. Erika Hamilton joined VuMedi to recap #SABCS23 Insights: "CAMBRIA 1 Study of Extended Adjuvant Therapy With Camizestrant vs. Standard ET in Patients With ER+/HER2- Early BC and an Intermediate/High Risk of Recurrence." Watch the full video on VuMedi. https://lnkd.in/eD4pdZqd #ClinicalTrials #OncologyResearch #BCSM #OncologyExpert

Phase 2 clinical trial update on NETs! 📊 Lenvatinib and pembrolizumab combo in advanced GI and thoracic NETs showed 10% partial response, with median PFS of 8 months. Also, 60% experienced grade 3 adverse events, leading to dose adjustments or discontinuation. The trial did not show sufficient response to be continued. More details in the article: https://ow.ly/hwrG50R0Vbj #MedEd